Market Trends of Global Anesthesia Gases Industry
Isoflurane Gas is Expected to Witness Significant Growth During the Forecast Period
Isoflurane is commonly used for the induction and maintenance of general anesthesia in the operating room. The increasing number of emergency departments, surgical interventions, and the rising geriatric population prone to chronic diseases are expected to drive the segment growth.
Due to the widespread applications and safety of isoflurane, its usage is likely to increase, which is expected to drive the segment growth over the study period. For instance, according to an article updated by NCBI in August 2022, isoflurane is a volatile anesthetic gas approved by the FDA for the induction and maintenance of general anesthesia. Unlike other common anesthesia gases, isoflurane is non-flammable. The source also stated that regarding cardiac function, isoflurane has minimal impact on left ventricular function. Still, it does cause a dose-dependent decrease in systemic vascular resistance due to mild beta-adrenergic stimulation. Thus, the increasing advantages of isoflurane are expected to boost its adoption during surgical procedures, propelling segment growth.
Companies offering anesthesia gas products are innovating, launching new products, and expanding their capabilities to fuel the availability of many anesthesia gases in the market, thus boosting segment growth over the study period. For instance, in October 2023, Sedana Medical received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) for Sedaconda (isoflurane) in the United Kingdom. In addition, as per the quarterly report of Piramal Pharma Limited in 2024, the company planned to expand its inhalation isoflurane anesthesia facility in India. These new product approvals and facility expansion are expected to increase the availability of anesthesia gas products, thereby driving market growth over the forecast period.
Thus, the adoption of isoflurane gas, coupled with new product approvals, is expected to increase during the forecast period due to its growing usage in surgeries and company activities such as product launches globally.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is likely to have a significant share of the overall market owing to the region's rising geriatric population and increased surgical procedures. According to the National Spinal Cord Injury Statistical Center, in 2022, about 30% of the patients with spinal cord injury (SCI) were re-hospitalized one or more times during any given year following injury. Among those re-hospitalized, the length of hospital stay averaged about 18 days in the United States. Hence, due to the rising number of spinal cord injuries in the United States, spinal cord surgeries are also expected to increase, leading to increased usage of anesthesia gases.
Moreover, the rising incidence of spinal cord injuries in Canada may increase the need for more surgical interventions using anesthesia and is expected to enhance the market growth in the region. For instance, according to an article published by Frontiers in November 2022, it is estimated that in Canada, more than 86,000 people are affected by spinal cord injuries every year, from either a traumatic or non-traumatic injury.
Furthermore, anesthesia gas manufacturing companies are expanding their facilities to meet high demand, which is expected to propel the market growth. For instance, as per the quarterly report of Piramal Pharma Limited in 2024, the company planned to expand its inhalation sevoflurane and desflurane anesthesia facility in the United States. Thus, the establishment of the new facility helps provide anesthesia gases to address the growing demand in the country, thereby boosting the market growth in the region.
Therefore, owing to the factors mentioned above, such as the rising geriatric population and increased surgical procedures, the market studied is anticipated to flourish in North America.
